{
  "pmid": "26549023",
  "abstract": "The scaffold protein KSR1, a novel therapeutic target for the treatment of  Merlin-deficient tumors.  Zhou L(1), Lyons-Rimmer J(1), Ammoun S(1), MÃ¼ller J(2)(3), Lasonder E(4), Sharma  V(4), Ercolano E(1), Hilton D(5), Taiwo I(1), Barczyk M(6), Hanemann CO(1).  Author information: (1)Institute of Translational and Stratified Medicine, Plymouth University  Peninsula Schools of Medicine and Dentistry, Plymouth, UK. (2)Warwick Medical School, University of Warwick, Coventry, UK. (3)Aston Medical Research Institute, Aston Medical School, Aston University,  Birmingham, UK. (4)School of Biomedical and Healthcare Sciences, Plymouth University Peninsula  Schools of Medicine and Dentistry, Plymouth, UK. (5)Department of Neuropathology, Derriford Hospital, Plymouth, UK. (6)Cell Biology, MRC Laboratory of Molecular Biology, Cambridge, UK.  Merlin has broad tumor-suppressor functions as its mutations have been  identified in multiple benign tumors and malignant cancers. In all schwannomas,  the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In  neurofibromatosis type 2, a dominantly inherited tumor disease because of the  loss of Merlin, patients suffer from multiple nervous system tumors and die on  average around age 40. Chemotherapy is not effective and tumor localization and  multiplicity make surgery and radiosurgery challenging and morbidity is often  considerable. Thus, a new therapeutic approach is needed for these tumors. Using  a primary human in vitro model for Merlin-deficient tumors, we report that the  Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase  (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of  Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show  that KSR1 overexpression is involved in many pathological phenotypes caused by  Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal  adhesion and, most importantly, increased proliferation and survival. Our data  demonstrate that KSR1 has a wider role than MEK1/2 in the development of  schwannomas because adhesion is more dependent on KSR1 than MEK1/2.  Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of  Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1  and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with  several Merlin downstream effectors, including E3 ubiquitin ligase CRL4(DCAF1).  Further functional studies suggests that KSR1 and DCAF1 may co-operate to  regulate schwannomas formation. Taken together, these findings suggest that KSR1  serves as a potential therapeutic target for Merlin-deficient tumors.  DOI: 10.1038/onc.2015.404 PMCID: PMC4861249 PMID: 26549023 [Indexed for MEDLINE]",
  "methods": "",
  "introduction": "",
  "results": "",
  "discussion": "",
  "fetched_at": "2026-02-16T15:43:43.344280",
  "abstract_length": 2806,
  "methods_length": 0,
  "introduction_length": 0,
  "results_length": 0,
  "discussion_length": 0
}